The stock of Sunshine Biopharma Inc (NASDAQ:SBFM) last traded at $0.06, up 7.14% from the previous session.
SBFM stock price is now -58.79% away from the 50-day moving average and -81.53% away from the 200-day moving average. The market capitalization of the company currently stands at $5.97M.
In other news, Slilaty Steve N., Chief Executive Officer bought 100,000 shares of the company’s stock on Mar 04 ’24. The stock was bought for $10,000 at an average price of $0.10. Upon completion of the transaction, the Chief Executive Officer now directly owns 130,000 shares in the company, valued at $7800.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 08 ’24, Chief Executive Officer Slilaty Steve N. bought 20,000 shares of the business’s stock. A total of $2,000 was incurred on buying the stock at an average price of $0.10. This leaves the insider owning 30,000 shares of the company worth $1800.0. A total of 7.55% of the company’s stock is owned by insiders.
During the past 12 months, Sunshine Biopharma Inc has had a low of $0.04 and a high of $1.40. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 5.00, and a quick ratio of 4.11. The fifty day moving average price for SBFM is $0.1417 and a two-hundred day moving average price translates $0.3219 for the stock.
The latest earnings results from Sunshine Biopharma Inc (NASDAQ: SBFM) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.04, beating analysts’ expectations of -$0.06 by 0.02. This compares to -$0.08 EPS in the same period last year. The net profit margin was -131.52% and return on equity was -85.87% for SBFM. The company reported revenue of $5.96 million for the quarter, compared to $0.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4379.7 percent. For the current quarter, analysts expect SBFM to generate $6.1M in revenue.
